পৃষ্ঠা 1 থেকে 467 ফলাফল
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010.
FIELD OF THE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009.
TECHNICAL FIELD
The
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008206, filed Nov. 19, 2010, which claims priority from Korea Patent Application 10-2010-0041249, filed May 3, 2010.
BACKGROUND OF THE
BACKGROUND
Obesity is a chronic condition that is characterized by a body mass index (BMI) over 25. Both congenital and environmental factors, such as exercise and eating habits, contribute to the disease. For instance, the hormone leptin has been shown to be involved in fat accumulation and
BACKGROUND
Obesity is a chronic condition that is characterized by a body mass index (BMI) over 25. Both congenital and environmental factors, such as exercise and eating habits, contribute to the disease. For instance, the hormone leptin has been shown to be involved in fat accumulation and
BACKGROUND
Obesity is a chronic condition that is characterized by a body mass index (BMI) over 25. Both congenital and environmental factors, such as exercise and eating habits, contribute to the disease. For instance, the hormone leptin has been shown to be involved in fat accumulation and
FIELD OF THE INVENTION
The present invention relates to a non-human animal model for obesity and uses of such an animal for studying and developing methods for identifying compounds for use in the regulation of insulin resistance in obesity and type II diabetes, as well as a method of treating
FIELD OF THE INVENTION
The present invention relates to a method for treating obesity, insulin resistance and dyslipidemia in mammals including humans through inhibition of PPAR.delta.(.beta.). This invention also relates to methods of screening for chemical entities that act to regulate
BACKGROUND OF THE INVENTION
Obesity and diabetes are among the most common human health problems in industrialized societies. Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals
BACKGROUND OF THE INVENTION
Obesity and diabetes are among the most common human health problems in industrialized societies. Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals
BACKGROUND
CD36 is a multifunctional receptor that is expressed in various types of cells and tissues including brain microglia and astrocytes as well as monocytes/macrophages and adipocytes. CD36 recognizes many ligands including oxidized or modified low density lipoprotein (oxLDL, mLDL),
BACKGROUND OF THE INVENTION
Insulin resistance in the peripheral tissues such as muscle and fat is associated with increased secretion of insulin by pancreatic .beta.-cells. The secreted insulin promotes glucose utilization and inhibits production of glucose by the liver. However, the pancreatic
BACKGROUND OF THE INVENTION
Insulin resistance in the peripheral tissues such as muscle and fat is associated with increased secretion of insulin by pancreatic .beta.-cells. The secreted insulin promotes glucose utilization and inhibits production of glucose by the liver. However, the pancreatic
BACKGROUND OF THE INVENTION
Insulin resistance in the peripheral tissues such as muscle and fat is associated with increased secretion of insulin by pancreatic .beta.-cells. The secreted insulin promotes glucose utilization and inhibits production of glucose by the liver. However, the pancreatic
The present invention relates to the use of ketoconazole or molecules resembling ketoconazole but with some side-chains, not affecting the biological activity compared to ketoconazole, changed for manufacturing drugs for treatment of diabetes mellitus type II.
The drug ketoconazole (e.g., under the